The lawsuit claims that three major healthcare companies were pushing up the price of insulin by 1,200 percent.

Units of CVS Health Corp., Cigna Group and UnitedHealth Group Inc. charged significantly more than the national average ...

Three major drug middlemenneedlessly marked up generic drugs for cancer, HIV, and multiple sclerosis to generate $7.3 billion ...

The FTC report found that from 2017 to 2022, three PBMs—UnitedHealth Group's Optum, CVS Health's CVS Caremark and Cigna's ...

The Federal Trade Commission said three top pharmacy suppliers made profits of 7,700 percent on a lifesaving hypertension ...

According to FTC’s latest report, units of CVS Health Corp., Cigna Group and UnitedHealth Group Inc. charged significantly ...

From 2017 to 2022, the companies marked up prices at their pharmacies by hundreds or thousands of percent, netting them $7.3 billion in revenue.

FTC report reveals significant markups by top PBMs on specialty drugs, driving $7.3 billion in revenue and raising costs for ...

For the second time in less than a year, the FTC has released a highly critical report of pharmacy benefit managers, or PBMs.

Cigna (CI) and UnitedHealth (UNH) significantly marked up prices for specialty generic drugs over a six-year period.

Wells Fargo analyst Stephen Baxter maintained a Buy rating on CVS Health (CVS – Research Report) on January 10 and set a price target of ...